Clinical Trial: A prospective phase II clinical trial to evaluate the efficacy and safety of irinotecan liposome combined with PD-L1 inhibitor in the second-line treatment of large cell neuroendocrine carcinoma of the lung (China)

China, Sept. 17 -- The Chinese Clinical Trial Registry (ChiCTR) received information related to the study titled 'A prospective phase II clinical trial to evaluate the efficacy and safety of irinotecan liposome combined with PD-L1 inhibitor in the second-line treatment of large cell neuroendocrine carcinoma of the lung'. The following are the other relevant details related to the trial:

Registration Number: ChiCTR2600132633

Registration Time: 2026/09/16

Type: Interventional study

Primary Sponsor: Cancer Hospital Chinese Academy of Medical Sciences

To know more, click on https://www.chictr.org.cn/showprojEN.html?proj=340534

Published by HT Digital Content Services with permission from Health Daily Digest....